

Cyrielle Fougereux

New vaccine technologies are required to rapidly respond to pandemics and trigger long-lasting protection. While mRNA vaccines have been a huge success in controlling the COVID-19 pandemic, the antibody responses induced by the mRNA vaccines are short-lived, necessitating frequent booster doses.

This talk will present a next-generation mRNA vaccine that utilizes a modular genetic vaccine platform encoding antigen-displaying virus-like-particles. The protein-based Tag/Catcher cVLP vaccine platform has previously been clinically proven and induced very potent immune responses even when administered without an adjuvant. This next-generation mRNA vaccine technology allows for rapid response due to the quick mRNA manufacture combined with high antibody response and longevity induced by the VLP display.